The session was attended by 73 member countries (including India), one member organization and 41 observer organizations including FAO & WHO.

The Committee had 12 agenda items, including three new work proposals on General requirements for protein supplements intended for bodybuilding; Methods of analysis for provisions in the Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants (CXS 72-1981); and International Prebiotic Guidelines for Use in Foods and Dietary Supplements.

Decisions on the important agenda items concerning India are as follows:

- **Agenda Item 4a: Review of Standard for Follow-up Formula (Essential composition requirements):** During discussion on protein, Committee decided to keep Protein Efficiency Ratio (PER) method along with Protein Digestibility Corrected Amino Acid Score (PDCAAS) which was supported by India also.
  The Committee decided to keep essential requirements for follow-up formula for older infants and for [product] for young children at Step 7. Further, an electronic working group (eWG) on follow-up formula was requested to provide further recommendations on Dextrose Equivalent (DE) for products not based on milk protein for comments and consideration by the next session of the Committee.

- **Agenda Item 4b: Review of Standard for Follow-up Formula (Structure of the Standard, preamble, scope, product definition and labelling):** During the discussions the Committee agreed the following based on consensus arrived by the member countries including India:
Not to refer the products as specially formulated and accordingly the word 'specially' was removed from the definition of both older infants and young children;

To classify follow-up formula for older infants as breast milk substitutes and accordingly labeling provisions has been revised;

To include young children in the list of prohibited pictures on the label of follow-up formula for older infants;

Not to allow cross promotion on the label of follow up formula for older infants and included a statement in this regard.

However, as there was no consensus regarding classifying [product] for young children as a breast milk substitute, Committee decided to defer the discussion to the next session. Further, the Committee also decided to advance Follow up formula for older infants to Step 5 for adoption by CAC42 and labelling provisions for the same will also be forwarded to 45 session of Codex Committee on Food Labelling (CCFL45) for endorsement. Discussion on product definition and labelling of [product] for young children and the structure of the Standard(s) and preamble(s) has been deferred for the next meeting.

- **Agenda Item 5: Proposed Draft Guideline for Ready-to-Use Therapeutic Foods (RUTF):** The Committee decided to keep the sections agreed till CCNFSDU40 at Step 4 and the remaining recommendations of the physical working group (PWG) including preamble will be considered in the next session. An eWG chaired by South Africa and co-chaired by Senegal and Uganda has been re-established to continue developing sections related to Food additives and Proteins for circulation for comments and consideration at its next session.

- **Agenda Item 6: Proposed draft definition for Bio fortification:** India supported continuing the work with a opinion that genetically engineered products/process need to be excluded from the scope of the definition which was already taken care by the footnote. The Committee decided to forward the drafted definition to CCFL with a request to consider if the definition would meet their intended needs and to clarify the intended use of the definition and where the definition would be best placed.